Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Merkel cell carcinoma has historically had dismal prognosis with limited cytotoxic chemotherapy options that provide durable control of metastatic disease. The advent of anti-programmed death protein (anti-PD1)/anti-programmed death-ligand 1 (anti-PD-L1) directed immunotherapy has shown initial prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloom, Brooke C., Augustyn, Alexander, Pezzi, Todd A., Menon, Hari, Mayo, Lauren L., Shah, Shalin J., Schwartz, David L., Chmura, Steven J., Johnson, Faye M., Welsh, James W., Chun, Stephen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459944/
https://www.ncbi.nlm.nih.gov/pubmed/31024834
http://dx.doi.org/10.3389/fonc.2019.00223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459944/
https://www.ncbi.nlm.nih.gov/pubmed/31024834
http://dx.doi.org/10.3389/fonc.2019.00223

Ejemplares similares